

MINDACT, validating a new prognostic tool



The trial enrolled
6,693
early-stage breast cancer patients



112
cancer centres
and hospitals



9
countries



47
million €
to fund the trial



- ✓ De-escalation of therapies
- ✓ Pioneering precision medicine
- ✓ Better and personalised treatment
- ✓ Potential savings for society
- ✓ Goldmine for future research



70-gene
prognosis signature

can help with decision-making
about giving
chemotherapy or not

Patient categories


Clinical &
genomic tests
indicate
low risk
of recurrence



Clinical &
genomic tests
indicate
high risk
of recurrence



Clinical &
genomic tests
are discordant



RANDOMISATION



46%

of patients
could be spared
unnecessary
chemotherapy

Highest scientific
evidence
level 1A

